CGON vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGON Captures Institutional Edge (3โ1 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CGON trades at N/M Forward P/E with -4293.5% operating margin (-3.7% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CGON Revenue | CVM Revenue | CGON Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | N/A | $0M | N/A | -1881.0% | CVM |
| FY2012 | N/A | $0M | N/A | -6772.3% | CVM |
| FY2013 | N/A | $0M | N/A | -12450.1% | CVM |
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2023 | $0M | N/A | -27180.9% | N/A | CGON |
| FY2024 | $0M | N/A | -10067.3% | N/A | CGON |
| FY2025 | $0M | N/A | -4722.1% | N/A | CGON |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGON | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.3B | $20.9M | Larger Scale | CGON |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -3.7% | -62.7% | Higher Growth | CGON |
| Operating Margin (TTM) Profitability | -4293.5% | 0.0% | Higher Margin | CVM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -28.3% | -252.5% | Higher ROE | CGON |
| 52-Week Range Position Momentum | 84% ($37โ$94) | 10% ($1โ$8) | Stronger Trend | CGON |
| Beta / 30D Volatility Risk Regime | 0.75ฮฒ ยท 89% Vol | 0.65ฮฒ ยท 120% Vol | Lower Realized Risk | CGON |
| Unified Institutional Score Composite Signal | 45.0 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | CVM |